The HER2 (human epidermal growth factor receptor 2) gene is part of a family of genes that play roles in regulating cell growth. The protein it makes is a tyrosine kinase growth factor receptor that a number of normal tissues express and which probably has a role in normal cell function, regulating growth and proliferation.
Australian researchers have identified a potentially treatable subtype of pancreatic cancer, which accounts for about 2% of new cases. This subtype expresses high levels of the HER2 gene. HER2-amplified breast and gastric cancers are currently treated with Herceptin.
A drug approved in Europe to treat osteoporosis has now been shown to stop the growth of breast cancer cells, even in cancers that have become resistant to current targeted therapies, according to a Duke Cancer Institute study.
Biocept, Inc., a privately-held, CLIA certified laboratory testing company focused on detection and analysis of circulating tumor cells and circulating tumor DNA in cancer patients, reported the publication in the journal Cancer Medicine of a paper entitled "Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer" on research performed with collaborators from the University of Texas MD Anderson Cancer Center.
Researchers at Johns Hopkins have identified a gene that, when repressed in tumor cells, puts a halt to cell growth and a range of processes needed for tumors to enlarge and spread to distant sites. The researchers hope that this so-called "master regulator" gene may be the key to developing a new treatment for tumors resistant to current drugs.
New results from a retrospective study conducted in Europe suggest that anti-HER2 treatments, like the widely used breast cancer agent trastuzumab (Herceptin), have anti-cancer effects in a small subset of patients with advanced non-small cell lung cancer (NSCLC) harboring specific HER2 protein mutations.
Triple negative breast cancer (TNBC) is a type of cancer that has none of the three markers that are currently used for targeted chemotherapy. These markers are estrogen receptor (ER), progesterone receptor (PR) and HER2.
Results from the PrefHer (Patient Preference for Subcutaneous (SC) versus Intravenous (IV) Herceptin) trial show that 92% of early HER2-positive breast cancer patients favoured quicker SC administration of Herceptin compared to the standard IV infusion.1 Presented at the St. Gallen Breast Cancer Conference in Switzerland.
Research led by Dr. Suresh Alahari, the Fred Brazda Professor of Biochemistry and Molecular Biology at LSU Health Sciences Center New Orleans and its Stanley S. Scott Cancer Center, details exactly how the Her2 cancer gene promotes the progression and spread of breast cancer cells.
Thomas Jefferson University will honor the renowned biotech researcher whose discoveries led to a slew of innovative drugs that revolutionized treatment including Herceptin-one of the first gene-based medications for breast cancer-with its prestigious Lennox K. Black International Prize for Excellence in Biomedical Research.
Breast cancer recurrence is a major problem after treatment of localized breast cancer. The risk of recurrence depends on several factors including the stage of presentation and the biology of the disease.
Approximately 20% of all breast cancer patients have overexpression of HER2 (human epidermal growth factor receptor 2), resulting in a more aggressive phenotype, and a poor prognosis.
It’s nearly a decade since the completion of the Human Genome Project, (1) which aimed to sequence the complete human genome.
Because cases of Triple-Negative Breast Cancer (TNBC) are so genetically different, whole-genome sequencing is needed to detect the subtle molecular differences that might point to specific treatments for individual patients.
Synta Pharmaceuticals Corp. - Ganetespib, a potent, second generation Hsp90 inhibitor, has demonstrated clinical activity in heavily pre-treated patients with HER2-positive and triple negative metastatic breast cancer according to Phase 2 clinical trial results presented by researchers from Memorial Sloan-Kettering Cancer Center at the San Antonio Breast Cancer Symposium.
A new study released this Wednesday revealed that breast cancer that is highly aggressive but caught early could be best treated with a combination of Herceptin and chemotherapy.
The results of a new study revealed that treatment for women with HER2-positive breast cancer – an aggressive form of the disease which is diagnosed in 10,000 British women each year – slowed the progression of tumors by 40 per cent compared with conventional drugs. Tests on 137 women showed that the new therapy – called T-DM1 – which combines the drug Herceptin with an antibody drug, instead of with standard chemotherapy, appeared to stop the cancer “in its tracks”.
Research into new methods to prevent and slow metastatic breast cancer will be presented this week at the Era of Hope conference, a scientific meeting hosted by the Department of Defense Breast Cancer Research Program.
A woman's ethnicity as well as her genetic makeup are two of the main risk factors for hereditary breast cancer. Research into understanding and treating hereditary breast cancer will be presented today at the Era of Hope conference, a scientific meeting hosted by the Department of Defense Breast Cancer Research Program.
ASLAN Pharmaceuticals Pte Ltd and Array BioPharma Inc. today announced a license agreement to develop Array's HER2 / EGFR inhibitor, ARRY-543, currently entering Phase 2 development for solid tumors.
The U.S. Food and Drug Administration today issued a new draft guidance to facilitate the development and review of companion diagnostics – tests used to help health care professionals determine whether a patient with a particular disease or condition should receive a particular drug therapy or how much of the drug to give.